Loading…
Efficacy of T Regulatory Cells, Th17 Cells and the Associated Markers in Monitoring Tuberculosis Treatment Response
Treatment monitoring is an essential aspect for tuberculosis (TB) disease management. Sputum smear microscopy is the only available tool for monitoring, but it suffers from demerits. Therefore, we sought to evaluate markers and cellular subsets of T regulatory (Treg) cells and T helper (Th) 17 cells...
Saved in:
| Published in: | Frontiers in immunology 2018-02, Vol.9, p.157-157 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c462t-c238ff0fed6a599bb7ca046a5c5ee2bc0de8002bea6fbdddd684eb2b55e15fd63 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c462t-c238ff0fed6a599bb7ca046a5c5ee2bc0de8002bea6fbdddd684eb2b55e15fd63 |
| container_end_page | 157 |
| container_issue | |
| container_start_page | 157 |
| container_title | Frontiers in immunology |
| container_volume | 9 |
| creator | Agrawal, Sonali Parkash, Om Palaniappan, Alangudi Natarajan Bhatia, Ashok Kumar Kumar, Santosh Chauhan, Devendra Singh Madhan Kumar, M |
| description | Treatment monitoring is an essential aspect for tuberculosis (TB) disease management. Sputum smear microscopy is the only available tool for monitoring, but it suffers from demerits. Therefore, we sought to evaluate markers and cellular subsets of T regulatory (Treg) cells and T helper (Th) 17 cells in pulmonary TB patients (PTB) for TB treatment monitoring. Peripheral blood mononuclear cells (PBMCs) were stimulated
(with purified protein derivative (PPD)) overnight which was followed by a polychromatic flow cytometry approach to study Treg and Th17 markers and cellular subsets in PTB (
= 12) undergoing antituberculous treatment (ATT). The baseline levels of these markers and cellular subsets were evaluated in normal healthy subjects (NHS). We observed a significant decrease in the expression of CD25 ( |
| doi_str_mv | 10.3389/fimmu.2018.00157 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9768104e18a949448c35a1ae45afe92f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_9768104e18a949448c35a1ae45afe92f</doaj_id><sourcerecordid>2007983858</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-c238ff0fed6a599bb7ca046a5c5ee2bc0de8002bea6fbdddd684eb2b55e15fd63</originalsourceid><addsrcrecordid>eNpVkc1v1DAQxSMEolXpnRPykQO7-DOxL0jVqkClVkgonK2JM951SeLFTpD2v8fdLVU7Fz_Z835j-1XVe0bXQmjz2YdxXNacMr2mlKnmVXXO6lquBOfy9TN9Vl3mfE9LSSOEUG-rM25kww3n51W-9j44cAcSPWnJT9wuA8wxHcgGhyF_Iu2ONSdNYOrJvENylXN0AWbsyR2k35gyCRO5i1MoxjBtSbt0mNwyxBwyaRPCPOI0F3jexynju-qNhyHj5eN6Uf36et1uvq9uf3y72Vzdrpys-bxyXGjvqce-BmVM1zUOqCzaKUTeOdqjppR3CLXv-lK1ltjxTilkyve1uKhuTtw-wr3dpzBCOtgIwR43YtpaSHNwA1rT1JpRiUyDkUZK7YQCBigVeDTcF9aXE2u_dCP2rrwnwfAC-vJkCju7jX-tKlze0AL4-AhI8c-CebZjyK78K0wYl2w5pY3RQitdWump1aWYc0L_NIZR-xC9PUZvH6K3x-iL5cPz6z0Z_gct_gHFV62e</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2007983858</pqid></control><display><type>article</type><title>Efficacy of T Regulatory Cells, Th17 Cells and the Associated Markers in Monitoring Tuberculosis Treatment Response</title><source>PubMed Central</source><creator>Agrawal, Sonali ; Parkash, Om ; Palaniappan, Alangudi Natarajan ; Bhatia, Ashok Kumar ; Kumar, Santosh ; Chauhan, Devendra Singh ; Madhan Kumar, M</creator><creatorcontrib>Agrawal, Sonali ; Parkash, Om ; Palaniappan, Alangudi Natarajan ; Bhatia, Ashok Kumar ; Kumar, Santosh ; Chauhan, Devendra Singh ; Madhan Kumar, M</creatorcontrib><description>Treatment monitoring is an essential aspect for tuberculosis (TB) disease management. Sputum smear microscopy is the only available tool for monitoring, but it suffers from demerits. Therefore, we sought to evaluate markers and cellular subsets of T regulatory (Treg) cells and T helper (Th) 17 cells in pulmonary TB patients (PTB) for TB treatment monitoring. Peripheral blood mononuclear cells (PBMCs) were stimulated
(with purified protein derivative (PPD)) overnight which was followed by a polychromatic flow cytometry approach to study Treg and Th17 markers and cellular subsets in PTB (
= 12) undergoing antituberculous treatment (ATT). The baseline levels of these markers and cellular subsets were evaluated in normal healthy subjects (NHS). We observed a significant decrease in the expression of CD25 (
<0.01) marker and percentage of T-cell subsets like CD4
CD25
(
<0.001) and CD4
CD25
CD39
(
<0.05) at the end of intensive phase (IP) as well as in the continuation phase (CP) of ATT. A decrease in CD25 marker expression and percentage of CD4
CD25
T cell subset showed a positive correlation to sputum conversion both in high and low sputum positive PTB. In eight PTB with cavitary lesions, only CD4
CD25
FoxP3 Treg subset manifested a significant decrease at the end of CP. Thus, results of this study show that CD25 marker and CD4
CD25
T cells can serve as better markers for monitoring TB treatment efficacy. The Treg subset CD4
CD25
FoxP3 may be useful for prediction of favorable response in PTB with extensive lung lesions. However, these findings have to be evaluated in a larger patient cohort.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2018.00157</identifier><identifier>PMID: 29472922</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Adult ; Antitubercular Agents - therapeutic use ; Biomarkers - analysis ; Cells, Cultured ; Drug Monitoring - methods ; Female ; Flow Cytometry ; Humans ; Immunology ; Interleukin-2 Receptor alpha Subunit - genetics ; Leukocytes, Mononuclear - drug effects ; Male ; Middle Aged ; monitoring ; T-Lymphocytes, Regulatory - immunology ; Th17 ; Th17 Cells - immunology ; treatment ; Treatment Outcome ; Treg ; Tuberculin - pharmacology ; tuberculosis ; Tuberculosis, Pulmonary - drug therapy ; Tuberculosis, Pulmonary - immunology ; Young Adult</subject><ispartof>Frontiers in immunology, 2018-02, Vol.9, p.157-157</ispartof><rights>Copyright © 2018 Agrawal, Parkash, Palaniappan, Bhatia, Kumar, Chauhan and Madhan Kumar. 2018 Agrawal, Parkash, Palaniappan, Bhatia, Kumar, Chauhan and Madhan Kumar</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-c238ff0fed6a599bb7ca046a5c5ee2bc0de8002bea6fbdddd684eb2b55e15fd63</citedby><cites>FETCH-LOGICAL-c462t-c238ff0fed6a599bb7ca046a5c5ee2bc0de8002bea6fbdddd684eb2b55e15fd63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810270/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810270/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29472922$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Agrawal, Sonali</creatorcontrib><creatorcontrib>Parkash, Om</creatorcontrib><creatorcontrib>Palaniappan, Alangudi Natarajan</creatorcontrib><creatorcontrib>Bhatia, Ashok Kumar</creatorcontrib><creatorcontrib>Kumar, Santosh</creatorcontrib><creatorcontrib>Chauhan, Devendra Singh</creatorcontrib><creatorcontrib>Madhan Kumar, M</creatorcontrib><title>Efficacy of T Regulatory Cells, Th17 Cells and the Associated Markers in Monitoring Tuberculosis Treatment Response</title><title>Frontiers in immunology</title><addtitle>Front Immunol</addtitle><description>Treatment monitoring is an essential aspect for tuberculosis (TB) disease management. Sputum smear microscopy is the only available tool for monitoring, but it suffers from demerits. Therefore, we sought to evaluate markers and cellular subsets of T regulatory (Treg) cells and T helper (Th) 17 cells in pulmonary TB patients (PTB) for TB treatment monitoring. Peripheral blood mononuclear cells (PBMCs) were stimulated
(with purified protein derivative (PPD)) overnight which was followed by a polychromatic flow cytometry approach to study Treg and Th17 markers and cellular subsets in PTB (
= 12) undergoing antituberculous treatment (ATT). The baseline levels of these markers and cellular subsets were evaluated in normal healthy subjects (NHS). We observed a significant decrease in the expression of CD25 (
<0.01) marker and percentage of T-cell subsets like CD4
CD25
(
<0.001) and CD4
CD25
CD39
(
<0.05) at the end of intensive phase (IP) as well as in the continuation phase (CP) of ATT. A decrease in CD25 marker expression and percentage of CD4
CD25
T cell subset showed a positive correlation to sputum conversion both in high and low sputum positive PTB. In eight PTB with cavitary lesions, only CD4
CD25
FoxP3 Treg subset manifested a significant decrease at the end of CP. Thus, results of this study show that CD25 marker and CD4
CD25
T cells can serve as better markers for monitoring TB treatment efficacy. The Treg subset CD4
CD25
FoxP3 may be useful for prediction of favorable response in PTB with extensive lung lesions. However, these findings have to be evaluated in a larger patient cohort.</description><subject>Adult</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Biomarkers - analysis</subject><subject>Cells, Cultured</subject><subject>Drug Monitoring - methods</subject><subject>Female</subject><subject>Flow Cytometry</subject><subject>Humans</subject><subject>Immunology</subject><subject>Interleukin-2 Receptor alpha Subunit - genetics</subject><subject>Leukocytes, Mononuclear - drug effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>monitoring</subject><subject>T-Lymphocytes, Regulatory - immunology</subject><subject>Th17</subject><subject>Th17 Cells - immunology</subject><subject>treatment</subject><subject>Treatment Outcome</subject><subject>Treg</subject><subject>Tuberculin - pharmacology</subject><subject>tuberculosis</subject><subject>Tuberculosis, Pulmonary - drug therapy</subject><subject>Tuberculosis, Pulmonary - immunology</subject><subject>Young Adult</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkc1v1DAQxSMEolXpnRPykQO7-DOxL0jVqkClVkgonK2JM951SeLFTpD2v8fdLVU7Fz_Z835j-1XVe0bXQmjz2YdxXNacMr2mlKnmVXXO6lquBOfy9TN9Vl3mfE9LSSOEUG-rM25kww3n51W-9j44cAcSPWnJT9wuA8wxHcgGhyF_Iu2ONSdNYOrJvENylXN0AWbsyR2k35gyCRO5i1MoxjBtSbt0mNwyxBwyaRPCPOI0F3jexynju-qNhyHj5eN6Uf36et1uvq9uf3y72Vzdrpys-bxyXGjvqce-BmVM1zUOqCzaKUTeOdqjppR3CLXv-lK1ltjxTilkyve1uKhuTtw-wr3dpzBCOtgIwR43YtpaSHNwA1rT1JpRiUyDkUZK7YQCBigVeDTcF9aXE2u_dCP2rrwnwfAC-vJkCju7jX-tKlze0AL4-AhI8c-CebZjyK78K0wYl2w5pY3RQitdWump1aWYc0L_NIZR-xC9PUZvH6K3x-iL5cPz6z0Z_gct_gHFV62e</recordid><startdate>20180205</startdate><enddate>20180205</enddate><creator>Agrawal, Sonali</creator><creator>Parkash, Om</creator><creator>Palaniappan, Alangudi Natarajan</creator><creator>Bhatia, Ashok Kumar</creator><creator>Kumar, Santosh</creator><creator>Chauhan, Devendra Singh</creator><creator>Madhan Kumar, M</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180205</creationdate><title>Efficacy of T Regulatory Cells, Th17 Cells and the Associated Markers in Monitoring Tuberculosis Treatment Response</title><author>Agrawal, Sonali ; Parkash, Om ; Palaniappan, Alangudi Natarajan ; Bhatia, Ashok Kumar ; Kumar, Santosh ; Chauhan, Devendra Singh ; Madhan Kumar, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-c238ff0fed6a599bb7ca046a5c5ee2bc0de8002bea6fbdddd684eb2b55e15fd63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Biomarkers - analysis</topic><topic>Cells, Cultured</topic><topic>Drug Monitoring - methods</topic><topic>Female</topic><topic>Flow Cytometry</topic><topic>Humans</topic><topic>Immunology</topic><topic>Interleukin-2 Receptor alpha Subunit - genetics</topic><topic>Leukocytes, Mononuclear - drug effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>monitoring</topic><topic>T-Lymphocytes, Regulatory - immunology</topic><topic>Th17</topic><topic>Th17 Cells - immunology</topic><topic>treatment</topic><topic>Treatment Outcome</topic><topic>Treg</topic><topic>Tuberculin - pharmacology</topic><topic>tuberculosis</topic><topic>Tuberculosis, Pulmonary - drug therapy</topic><topic>Tuberculosis, Pulmonary - immunology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Agrawal, Sonali</creatorcontrib><creatorcontrib>Parkash, Om</creatorcontrib><creatorcontrib>Palaniappan, Alangudi Natarajan</creatorcontrib><creatorcontrib>Bhatia, Ashok Kumar</creatorcontrib><creatorcontrib>Kumar, Santosh</creatorcontrib><creatorcontrib>Chauhan, Devendra Singh</creatorcontrib><creatorcontrib>Madhan Kumar, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Agrawal, Sonali</au><au>Parkash, Om</au><au>Palaniappan, Alangudi Natarajan</au><au>Bhatia, Ashok Kumar</au><au>Kumar, Santosh</au><au>Chauhan, Devendra Singh</au><au>Madhan Kumar, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of T Regulatory Cells, Th17 Cells and the Associated Markers in Monitoring Tuberculosis Treatment Response</atitle><jtitle>Frontiers in immunology</jtitle><addtitle>Front Immunol</addtitle><date>2018-02-05</date><risdate>2018</risdate><volume>9</volume><spage>157</spage><epage>157</epage><pages>157-157</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>Treatment monitoring is an essential aspect for tuberculosis (TB) disease management. Sputum smear microscopy is the only available tool for monitoring, but it suffers from demerits. Therefore, we sought to evaluate markers and cellular subsets of T regulatory (Treg) cells and T helper (Th) 17 cells in pulmonary TB patients (PTB) for TB treatment monitoring. Peripheral blood mononuclear cells (PBMCs) were stimulated
(with purified protein derivative (PPD)) overnight which was followed by a polychromatic flow cytometry approach to study Treg and Th17 markers and cellular subsets in PTB (
= 12) undergoing antituberculous treatment (ATT). The baseline levels of these markers and cellular subsets were evaluated in normal healthy subjects (NHS). We observed a significant decrease in the expression of CD25 (
<0.01) marker and percentage of T-cell subsets like CD4
CD25
(
<0.001) and CD4
CD25
CD39
(
<0.05) at the end of intensive phase (IP) as well as in the continuation phase (CP) of ATT. A decrease in CD25 marker expression and percentage of CD4
CD25
T cell subset showed a positive correlation to sputum conversion both in high and low sputum positive PTB. In eight PTB with cavitary lesions, only CD4
CD25
FoxP3 Treg subset manifested a significant decrease at the end of CP. Thus, results of this study show that CD25 marker and CD4
CD25
T cells can serve as better markers for monitoring TB treatment efficacy. The Treg subset CD4
CD25
FoxP3 may be useful for prediction of favorable response in PTB with extensive lung lesions. However, these findings have to be evaluated in a larger patient cohort.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>29472922</pmid><doi>10.3389/fimmu.2018.00157</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1664-3224 |
| ispartof | Frontiers in immunology, 2018-02, Vol.9, p.157-157 |
| issn | 1664-3224 1664-3224 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_9768104e18a949448c35a1ae45afe92f |
| source | PubMed Central |
| subjects | Adult Antitubercular Agents - therapeutic use Biomarkers - analysis Cells, Cultured Drug Monitoring - methods Female Flow Cytometry Humans Immunology Interleukin-2 Receptor alpha Subunit - genetics Leukocytes, Mononuclear - drug effects Male Middle Aged monitoring T-Lymphocytes, Regulatory - immunology Th17 Th17 Cells - immunology treatment Treatment Outcome Treg Tuberculin - pharmacology tuberculosis Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - immunology Young Adult |
| title | Efficacy of T Regulatory Cells, Th17 Cells and the Associated Markers in Monitoring Tuberculosis Treatment Response |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T14%3A50%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20T%20Regulatory%20Cells,%20Th17%20Cells%20and%20the%20Associated%20Markers%20in%20Monitoring%20Tuberculosis%20Treatment%20Response&rft.jtitle=Frontiers%20in%20immunology&rft.au=Agrawal,%20Sonali&rft.date=2018-02-05&rft.volume=9&rft.spage=157&rft.epage=157&rft.pages=157-157&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2018.00157&rft_dat=%3Cproquest_doaj_%3E2007983858%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c462t-c238ff0fed6a599bb7ca046a5c5ee2bc0de8002bea6fbdddd684eb2b55e15fd63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2007983858&rft_id=info:pmid/29472922&rfr_iscdi=true |